×
SciSparc EBIT 2017-2024 | SPRC
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
SciSparc ebit from 2017 to 2024. Ebit can be defined as earnings before interest and taxes.
View More
SciSparc EBIT 2017-2024 | SPRC
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
SciSparc ebit from 2017 to 2024. Ebit can be defined as earnings before interest and taxes.
Related Stocks
Company Name
Market
Cap
Chugai Pharmaceutical (CHGCY)
$69.6B
Zoetis (ZTS)
$67.5B
Daiichi Sankyo, - (DSNKY)
$48.8B
Takeda Pharmaceutical (TAK)
$48.2B
BeOne Medicines - (ONC)
$35B
Sandoz Group AG (SDZNY)
$26.3B
Summit Therapeutics (SMMT)
$19.5B
Merck (MKKGY)
$16.7B
Shionogi (SGIOY)
$14.9B
United Therapeutics (UTHR)
$14.2B
Neurocrine Biosciences (NBIX)
$13.2B
Orion OYJ (ORINY)
$11.2B
IPSEN (IPSEY)
$10.6B
Eisai (ESAIY)
$9.2B
Madrigal Pharmaceuticals (MDGL)
$8.7B
Corcept Therapeutics (CORT)
$7.6B
Grifols, S.A (GRFS)
$7.3B
Ionis Pharmaceuticals (IONS)
$6.9B
Stevanato Group S.p.A (STVN)
$6.8B
Hikma Pharmaceuticals Plc (HKMPF)
$5.4B
Ono Pharmaceutical (OPHLF)
$5.4B
Soleno Therapeutics (SLNO)
$3.6B
AMNEAL PHARMACEUTICALS, INC (AMRX)
$2.9B
NewAmsterdam Pharma (NAMS)
$2.9B
Crinetics Pharmaceuticals (CRNX)
$2.8B
Hypermarcas (HYPMY)
$2.6B
Catalyst Pharmaceuticals (CPRX)
$2.5B
Centessa Pharmaceuticals (CNTA)
$2.4B
Ocular Therapeutix (OCUL)
$2.1B
Endo (NDOI)
$1.8B